Flag of the European Union EU Clinical Trials Register Help

Clinical trials for eli lilly

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,061 result(s) found for: eli lilly. Displaying page 2 of 54.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-002354-23 Sponsor Protocol Number: H6D-MC-LVHV Start Date*: Information not available in EudraCT
    Sponsor Name:Eli Lilly and Company
    Full Title: A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    15.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) IT (Prematurely Ended) AT (Completed) NL (Completed) PL (Completed) ES (Completed) RO (Ongoing) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002328-42 Sponsor Protocol Number: I1F-MC-RHBE Start Date*: 2015-01-21
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I1F-MC-RHBE A Multicenter, Randomized, Double-Blind, Placebo-Controlled 24-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Diseas...
    Medical condition: Arthritic Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003229-14 Sponsor Protocol Number: I6T-MC-AMAN Start Date*: 2018-10-15
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active ...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) LV (Completed) CZ (Completed) LT (Completed) ES (Ongoing) BE (Completed) HU (Completed) AT (Completed) SK (Completed) DK (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-003938-27 Sponsor Protocol Number: I1F-MC-RHBX Start Date*: 2016-06-06
    Sponsor Name:Eli Lilly and Company
    Full Title: A 52 Week Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients with Nonradiographic Axial Spondyloa...
    Medical condition: bDMARD Naive Patients with Nonradiographic Axial Spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10076297 Non-radiographic axial spondyloarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) RO (Completed) FI (Completed) CZ (Completed) AT (Completed) PL (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-003299-30 Sponsor Protocol Number: I6T-MC-AMAH Start Date*: 2018-12-11
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Long-Term Extension to Evaluate the Long Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) PL (Prematurely Ended) FR (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003686-17 Sponsor Protocol Number: I4V-MC-JADY Start Date*: 2013-05-29
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SK (Completed) CZ (Prematurely Ended) BE (Completed) PL (Completed) SE (Completed) GB (Completed) HU (Completed) AT (Completed) DK (Completed) DE (Completed) PT (Completed) NL (Completed) ES (Completed) LV (Completed) LT (Completed) GR (Completed) SI (Completed) HR (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005356-99 Sponsor Protocol Number: I8B-MC-ITRM Start Date*: 2017-08-01
    Sponsor Name:Eli Lilly and Company
    Full Title: A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, ...
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10020639 Hyperglycemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) SK (Completed) DE (Completed) AT (Completed) PL (Completed) GR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2025-000001-16 Sponsor Protocol Number: I4V-JE-JAJE Start Date*: 2025-02-19
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients with NNS/CANDLE, SAVI, and AGS
    Medical condition: Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy with Onset in Infancy, Aicardi Goutieres Sy...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10073960 CANDLE syndrome PT
    21.1 10047065 - Vascular disorders 10047115 Vasculitis PT
    27.1 10010331 - Congenital, familial and genetic disorders 10054935 Aicardi's syndrome PT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2025-000102-42 Sponsor Protocol Number: H9X-MC-GBGS Start Date*: 2025-07-11
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less than 18 Y...
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    28.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2015-005358-36 Sponsor Protocol Number: I8B-MC-ITRO Start Date*: 2019-03-18
    Sponsor Name:Eli Lilly and Company
    Full Title: I8B MC ITRO A Prospective, Randomized, Double Blind Comparison of LY900014 to Humalog in Adults with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
    Medical condition: Diabetes Mellitus, Type 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) AT (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004350-26 Sponsor Protocol Number: I1F-MC-RHBA Start Date*: 2012-08-14
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Completed) NL (Completed) AT (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004362-26 Sponsor Protocol Number: I3Y-MC-JPCF Start Date*: 2017-08-14
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High-Risk, Node-Positive, ...
    Medical condition: Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2018-001726-26 Sponsor Protocol Number: I4V-MC-JAIY Start Date*: 2018-11-06
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Mode...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004622-28 Sponsor Protocol Number: I5Q-MC-CGAT Start Date*: 2021-02-22
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age with Chronic Migraine – the REBUILD-2 Study
    Medical condition: Chronic Migraine
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10066636 Chronic migraine LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) DE (Completed) FR (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006088-61 Sponsor Protocol Number: I8R-MC-IGBO Start Date*: 2024-03-05
    Sponsor Name:Eli Lilly and Company
    Full Title: An Open-Label, Multi-Center, Single-Dose Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Nasal Glucagon in Pediatric Patients with Type 1 Diabetes Aged 1 to <4 y...
    Medical condition: severe hypoglycemia
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-005191-35 Sponsor Protocol Number: J2G-MC-JZJX Start Date*: 2021-11-22
    Sponsor Name:Eli Lilly and Company
    Full Title: LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positi...
    Medical condition: Adjuvant Selpercatinib following definitive locoregional treatment in male or female patients with stage IB-IIIA RET fusion positive NSCLC
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) AT (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) NO (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002204-84 Sponsor Protocol Number: I6T-MC-AMAG Start Date*: 2017-02-01
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects with Active Crohn’s Disease (SERENITY)
    Medical condition: Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) HU (Completed) AT (Completed) NL (Completed) PL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001577-97 Sponsor Protocol Number: The PAGe study Start Date*: 2005-11-09
    Sponsor Name:Gunnar Hillerdal
    Full Title: Treatment of locally advanced or metastatic non-small cell lung cancer with Pemetrexed (Alimta) and Gemcitabine or Gemcitabine and Carboplatin: The PAGe study.
    Medical condition: Icke småcellig lungcancer i stadium IIIB eller IV.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005028-11 Sponsor Protocol Number: I4V-MC-JAIM Start Date*: 2019-10-24
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) HU (Completed) PL (Completed) BE (Completed) ES (Prematurely Ended) GR (Completed) NL (Completed) HR (Completed) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001884-38 Sponsor Protocol Number: I5Q-MC-CGAJ Start Date*: 2015-12-07
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients with Migraine.
    Medical condition: Episodic or chronic migraine headache
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Apr 22 17:18:34 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA